PHARMACOKINETICS OF ACRIDINE-4-CARBOXAMIDE IN THE RAT, WITH EXTRAPOLATION TO HUMANS

被引:11
作者
PAXTON, JW
YOUNG, D
ROBERTSON, IGG
机构
[1] Department of Pharmacology and Clinical Pharmacology, University of Auckland School of Medicine, Auckland
关键词
ACRIDINE-CARBOXAMIDE; PHARMACOKINETICS;
D O I
10.1007/BF00686180
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The pharmacokinetics of N-[2-(dimethyl-amino)ethyl]acridine-4-carboxamide (AC) were investigated in rats after i.v. administration of 18, 55 and 81 mumol/kg [H-3]-AC. The plasma concentration-time profiles of AC (as measured by high-performance liquid chromatography) typically exhibited biphasic elimination kinetics over the 8-h post-administration period. Over this dose range, AC's kinetics were first-order. The mean (+/- SD) model-independent pharmacokinetic parameters were: clearance (Cl), 5.3 +/- 1.11 h-1 kg-1; steady-state volume of distribution (V(ss)), 7.8 +/- 3.0 1/kg; mean residence time (MRT), 1. 5 +/- 0.4 h; and terminal elimination . half-life (t1/2Z), 2.1 +/- 0.7 h (n = 10). The radioactivity levels (expressed as AC equivalents) in plasma were 1.3 times the AC concentrations recorded at 2 min (the first time point) and remained relatively constant for 1-8 h after AC administration. By 6 h, plasma radioactivity concentration were 20 times greater than AC levels. Taking into account the species differences in the unbound AC fraction in plasma (mouse, 16.3%; rat, 14.8%; human, 3.4%), allometric equations were developed from rat and mouse pharmacokinetic data that predicted a Cl value of 0.075 (range, 0.05 -0. 10; 95% confidence limits) 1 h-1 kg-1 and a V(ss) value of 0.63 (range, 0.2 - 1. 1) 1/kg for total drug concentrations in humans.
引用
收藏
页码:323 / 325
页数:3
相关论文
共 12 条
[1]  
ARLIN ZA, 1983, CANCER TREAT REP, V67, P967
[2]   POTENTIAL ANTITUMOR AGENTS .50. INVIVO SOLID-TUMOR ACTIVITY OF DERIVATIVES OF N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE [J].
ATWELL, GJ ;
REWCASTLE, GW ;
BAGULEY, BC ;
DENNY, WA .
JOURNAL OF MEDICINAL CHEMISTRY, 1987, 30 (04) :664-669
[3]  
EVANS SMH, 1993, IN PRESS J PHARM PHA
[4]  
EVANS SMH, 1992, THESIS U AUCKLAND
[5]   SELECTIVITY OF N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE TOWARDS LEWIS LUNG-CARCINOMA AND HUMAN-TUMOR CELL-LINES INVITRO [J].
FINLAY, GJ ;
BAGULEY, BC .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1989, 25 (02) :271-277
[6]  
HARDY JR, 1988, CANCER RES, V48, P6496
[7]  
KESTELL P, 1990, CANCER RES, V50, P503
[8]   PHARMACOKINETICS AND TOXICITY OF THE ANTITUMOR AGENT N-[2-(DIMETHYLAMINO)ETHYL]ACRIDINE-4-CARBOXAMIDE AFTER IV ADMINISTRATION IN THE MOUSE [J].
PAXTON, JW ;
YOUNG, D ;
EVANS, SMH ;
KESTELL, P ;
ROBERTSON, IGC ;
CORNFORD, EM .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1992, 29 (05) :379-384
[9]  
PAXTON JW, 1990, CANCER RES, V50, P2692
[10]   ALPHA-1 ACID GLYCOPROTEIN CONCENTRATIONS AND PROPRANOLOL BINDING IN ELDERLY PATIENTS WITH ACUTE ILLNESS [J].
PAXTON, JW ;
BRIANT, RH .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 18 (05) :806-810